|
|
View Clinical Trial (Medical Research Study)
|
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402 - NCT00659373-63131 (Clinical Trial 215549)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy215549.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Saint Louis |
|
State:
|
|
MO |
| Zip Code: |
|
63131 |
| Conditions: |
|
Breast Cancer - Cognitive/Functional Effects - Fatigue - Psychosocial Effects of Cancer and Its Treatment - Sleep Disorders |
| Purpose: |
|
RATIONALE: Learning about the long-term effects of tamoxifen and ovarian function
suppression on brain function may help doctors plan cancer treatment.
PURPOSE: This study is looking at brain function in premenopausal women who are receiving
tamoxifen with or without ovarian function suppression for early-stage breast cancer on
clinical trial IBCSG-2402.
|
| Study summary: |
|
OBJECTIVES:
Primary:
- To evaluate and compare changes in cognitive function over 1 year in premenopausal
breast cancer patients who receive adjuvant tamoxifen with or without ovarian function
suppression (OFS).
Secondary:
- To compare the effect of tamoxifen with OFS versus exemestane with OFS on cognitive
function over 1 year.
- To compare the effect of tamoxifen alone versus exemestane with OFS on cognitive
function over 1 year.
- To evaluate and compare changes in cognitive function over 5 years and 6 years between
the 3 treatment groups (pending funding becoming available for the year 5 and 6
measures) on clinical trial IBCSG-2402.
- To explore the impact of receiving or not receiving prior chemotherapy on changes in
cognitive function.
- To explore the relationship between subjective and objective cognitive function.
- To explore the relationship between cognitive function, psychological distress,
fatigue, insomnia, and quality of life.
OUTLINE: This is a multicenter study.
Patients undergo objective cognitive function assessment over 20-25 minutes, using the
CogState computerized test battery, which consists of five tasks that measure the speed of
psychomotor function, visual attention, working memory and the accuracy of working memory,
learning and memory and executive function (all non-verbal). They undergo subjective
cognitive function assessment, using the Cognitive Failures Questionnaire (CFQ), a 25-item
self-report measure that assesses a person's failures in memory, perception, and motor
function over the past 6 months. Patients also complete General Health Questionnaire -12
(measuring psychologic distress), Brief Fatigue Inventory, NCI Common Terminology Criteria
for Adverse Events, and a patient-rated linear analogue self-assessment (LASA) scale
measuring insomnia. Patients complete these assessments at baseline (after registration to
clinical trial IBCSG-2402, but before beginning protocol therapy) and at 1, 5, and 6 years
after randomization on IBCSG-2402.
Relevant clinical factors, such as age, adjuvant chemotherapy, co-morbidity and concomitant
medications are assessed. In addition, language, education, psychiatric and neurological
history, alcohol consumption and right/left handedness are also assessed. |
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Histologically confirmed breast cancer
- Completely resected disease
- Registered for clinical trial IBCSG-2402, but not yet started protocol hormonal
therapy
- Has not yet received any of the following adjuvant endocrine therapy, either
before or after registration on IBCSG-2402:
- Tamoxifen, exemestane, or gonadotropin-releasing hormone (GnRH) agonist
- Ovarian irradiation
- Bilateral oophorectomy
- Hormone receptor status:
- Estrogen and/or progesterone receptor positive
- Each tumor must be hormone receptor positive
PATIENT CHARACTERISTICS:
- Premenopausal
- Can speak and read the local language(s) fluently
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics |
|
|
|
| Study is available at: |
|
Missouri Baptist Cancer Center
Saint Louis, MO 63131
United States
Primary Contact:
Alan P. Lyss, MD
Phone: 314-996-5514 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|